| |
It's rare to see a small biotech actually run the full gauntlet and come out the other side. This is SURGING again today, so keep a close eye on it! | TODAY'S TOP ALERT! | Citius Oncology (Nasdaq: CTOR) | | Hey Folks, Jeff Bishop here, | Stocks are rallying today to try to end the week in the green. That would certainly boost the holiday cheer going into the weekend! | If you've followed my "tactical trade" ideas this week, you already have something to be thankful for… | On Wednesday morning, I brought a pharma stock to your attention that had just launched its first commercial product this month: Citius Oncology (CTOR)*. | It just wrapped up a big capital raise last week, and I thought it was setting up for a potential rally. | It wound up surging double-digits intraday, but I alerted it again yesterday, and wrote you, "because the stock is green again in the pre-market as of this writing, and I think this bottom-bounce has room to run from here." | Here we are on the third day after my alert, and the stock is once again surging double-digits: | | As of this writing, it's now up more than 24% since my initial alert on Wednesday. | And while CTOR has clearly made a "bottom bounce," it still hasn't come near its high from earlier this month, so we could still see great things from it as we head into the weekend. | This has been one of the most explosive stocks to watch this week – I hope you didn't miss it! | 💥Stay dialed in to CTOR to watch the action pay out! | To Your Success, |  | Jeff Bishop |
| | *ISSUER- SPONSORED DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/ | Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call "typical." | Just a quick heads up about this ad you're reading—as we've said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received sixty five thousand dollars (cash) from Citius Oncology (via Sica Media) for advertising Citius Oncology for a three day marketing program starting on December 17, 2025. | It might seem obvious, but while our client claims not to own any shares in Citius Oncology, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case. | Now, diving right into Citius Oncology might sound exciting. But remember, it's like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you're doing. That's why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r. | Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We're simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We're obviously biased in our writing. We're not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as "forward-L00king statements" under the securities acts, so take those with a grain of salt. As with all forecasts, they're not set in stone, often wrong, and we certainly can't know where the Company's earnings, business, or share price will be tomorrow or a year from now. | Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, | Neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep's with the SEC, any state securities regulatory authority, or any self-regu1atory organization. | So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture. |
|
|
|
Tidak ada komentar:
Posting Komentar